Dr. Garcia Discusses the LATITUDE Study in Prostate Cancer

Jorge Garcia, MD
Published: Monday, Jul 31, 2017



Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the LATITUDE study in prostate cancer.

This randomized phase III study randomized patients to receive either standard therapy with androgen-deprivation therapy (ADT) with placebo or ADT with abiraterone acetate (Zytiga) and prednisone at 5 mg per day.

Garcia says that LATITUDE has changed the standard of care—adding abiraterone upfront has helped patients live longer, and has reduced the risk of relapse.
 


Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the LATITUDE study in prostate cancer.

This randomized phase III study randomized patients to receive either standard therapy with androgen-deprivation therapy (ADT) with placebo or ADT with abiraterone acetate (Zytiga) and prednisone at 5 mg per day.

Garcia says that LATITUDE has changed the standard of care—adding abiraterone upfront has helped patients live longer, and has reduced the risk of relapse.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x